These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34193193)

  • 21. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis.
    Jacob S; Viegas S; Leite MI; Webster R; Cossins J; Kennett R; Hilton-Jones D; Morgan BP; Vincent A
    Arch Neurol; 2012 Aug; 69(8):994-1001. PubMed ID: 22689047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
    Bi Z; Cao Y; Gui M; Lin J; Zhang Q; Li Y; Ji S; Bu B
    Neurol Sci; 2023 Apr; 44(4):1383-1391. PubMed ID: 36469201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays.
    Yan C; Zhao R; Song J; Feng X; Xi J; Luo S; Zhong H; Zhou S; Li W; Zhao C
    J Neuroimmunol; 2020 Dec; 349():577403. PubMed ID: 32992216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.
    Bi Z; Zhan J; Zhang Q; Gao H; Yang M; Ge H; Gui M; Lin J; Bu B
    Front Immunol; 2023; 14():1177249. PubMed ID: 37266422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study.
    Hendricks TM; Bhatti MT; Hodge DO; Chen JJ
    Am J Ophthalmol; 2019 Sep; 205():99-105. PubMed ID: 31077669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.
    Lu J; Zhong H; Jing S; Wang L; Xi J; Lu J; Zhou L; Zhao C
    Muscle Nerve; 2020 Mar; 61(3):311-315. PubMed ID: 31875994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
    Heo YA
    CNS Drugs; 2023 May; 37(5):467-473. PubMed ID: 37000339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic accuracy and clinical utility of bed side tests versus laboratory tests in the diagnosis of ocular myasthenia.
    Sivakumar P; Tagare S; Kumar M
    Indian J Ophthalmol; 2022 Apr; 70(4):1331-1337. PubMed ID: 35326049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.
    Vincent A; Newsom-Davis J
    J Neurol Neurosurg Psychiatry; 1985 Dec; 48(12):1246-52. PubMed ID: 4087000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.
    Ruan Z; Tang Y; Gao T; Li C; Guo R; Sun C; Huang X; Li Z; Chang T
    CNS Neurosci Ther; 2024 Jun; 30(6):e14793. PubMed ID: 38894580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis of Ocular Myasthenia Gravis in an Argentinian Population.
    Aguirre F; Villa AM
    Eur Neurol; 2018; 79(3-4):113-117. PubMed ID: 29428956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country.
    Mathew T; Thomas K; K John S; Venkatesh S; Nadig R; Badachi S; Souza DD; Sarma G; Parry GJ
    J Cent Nerv Syst Dis; 2021; 13():11795735211016080. PubMed ID: 34045914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
    Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
    Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zilucoplan: First Approval.
    Shirley M
    Drugs; 2024 Jan; 84(1):99-104. PubMed ID: 38093160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
    Datta S; Singh S; Govindarajan R
    J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis.
    Jia D; Zhang F; Li H; Shen Y; Jin Z; Shi FD; Zhang C
    Aging Dis; 2024 Apr; 15(2):824-830. PubMed ID: 37450932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acetylcholine receptor antibody in the diagnosis of myasthenia gravis.
    Nicholson GA; McLeod JG; Griffiths LR
    Med J Aust; 1983 Oct; 2(7):334-7. PubMed ID: 6621466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
    Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
    Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.